We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Robotic Next Generation Sequencing Platform Accurately Screens Thousands of COVID-19 Samples at Once

By LabMedica International staff writers
Posted on 04 Mar 2021
A robotics platform to screen thousands of COVID-19 samples at once has the potential to revolutionize how labs track the spread of viruses and other pathogens, according to new findings.

The study by researchers from the Lunenfeld-Tanenbaum Research Institute (LTRI) at Sinai Health (Toronto, ON, Canada) found that their next-generation, ultra-high-throughput sequencing platform, called C19-SPAR-Se, has a sensitivity rate greater than 95% in positive cases during peak onset. More...
The platform is also cost-effective. The study notes it only costs about USD 8 per test when running thousands of samples at once, as the cost per sample decreases due to economies of scale.

"Identifying positive samples quickly and accurately is critical in beating this pandemic," said Dr. Jeff Wrana, senior investigator at the LTRI and professor in the Department of Molecular Genetics at the University of Toronto. "With new and potentially dangerous variants now circulating, this is a platform that is scalable, automated and capable of analyzing thousands of COVID-19 patient samples in a single instrument run."

Related Links:
Lunenfeld-Tanenbaum Research Institute


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.